Last reviewed · How we verify
Nurtec Odt (Rimegepant Sulfate)
Rimegepant is a calcitonin gene-related peptide receptor antagonist.
NURTEC ODT is a CGRP receptor antagonist indicated for acute and preventive treatment of migraine in adults. The drug demonstrates moderate oral bioavailability (64%) with a half-life of 11 hours and is primarily metabolized by CYP3A4, requiring careful management of drug interactions. Key contraindications include hypersensitivity reactions including anaphylaxis, and concomitant use with strong CYP3A4 inhibitors must be avoided. The drug's efficacy may be affected by food intake and requires dose spacing considerations when used with moderate CYP3A4 inhibitors or P-gp inhibitors.
At a glance
| Generic name | Rimegepant Sulfate |
|---|---|
| Sponsor | Pfizer |
| Drug class | CGRP receptor antagonist |
| Target | Calcitonin gene-related peptide (CGRP) receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2020 |
| Annual revenue | 1424 |
Mechanism of action
Rimegepant works by blocking the calcitonin gene-related peptide receptor, a key mediator in migraine pathophysiology. CGRP is a neuropeptide involved in pain transmission and neuroinflammation associated with migraine. By antagonizing the CGRP receptor, rimegepant reduces the signaling cascade that leads to migraine symptoms.
Approved indications
- Migraine
- Prevention of migraine attacks
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Sinusitis
- Covid-19
- Nausea
- Protein urine present
- Blood creatine phosphokinase increased
- Urinary tract infection
- Anaemia
- Proteinuria
- Photophobia
- Blood urine present
Drug interactions
- Strong CYP3A4 inhibitors
- Moderate CYP3A4 inhibitors
- Strong and moderate CYP3A inducers
- Potent P-gp inhibitors (amiodarone, cyclosporine, lapatinib, quinidine, ranolazine)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nurtec Odt CI brief — competitive landscape report
- Nurtec Odt updates RSS · CI watch RSS
- Pfizer portfolio CI